Australia’s medtech Ovum secures $4 M to develop AI infrastructure for women
In just one year after raising $1.7 million in a pre-seed round, Ovum, an Australian women’s health startup started by Ariella Heffernan-Marks, has tripled its valuation by raising $4 million in seed capital to solve the gender health gap.
Admiralty Capital Group led the round, according to a statement released by Ovum on Tuesday. Antler, Giant Leap, Aviron Investments, Foggy Valley Aotearoa, Brisbane Angels, and Think & Grow participated, while LaunchVic contributed more money through The Alice Anderson Fund.
Ovum is developing AI infrastructure for women’s health that records symptoms, lifestyle, biometrics, stages of reproductive health, prescription drugs, appointments, and medical reports into a single longitudinal memory. In clinical contexts, it can assist women advocate for themselves by producing health summaries and questions that are ready for an appointment.
With over 20,000 downloads, 60,000 women’s health data insights collected, and over 113,000 AI health discussions from women aged 15 to 84, Ovum has experienced a 30% monthly growth since its August 2025 launch.
According to Amanda Andriano, Founding Partner of Admiralty Capital Group, Ovum creates the groundwork for a firm of global significance by combining goal, market timing, and technical capability with an outstanding founder.
According to Heffernan-Marks, the cash enables the business to responsibly expand its goals while creating a platform based on consent, privacy, and clinical integrity.
According to Ovum, 83% of its users have chosen to contribute anonymized data for research purposes, and the data is handled in accordance with international standards including GDPR and SOC 2 Type II. Ovum began clinical trials with St George Hospital and the Royal Hospital for Women earlier this year to evaluate AI as a preventative health tool for women.
